Zhongguancun Shuimu Medical Completes RMB 100 Million Series A Funding Round Led by Yuansheng Venture and Med-Fine Capital

Recently, Beijing Shuimu Zhonghui Science and Technology Development Co., Ltd. (hereinafter referred to as “Shuimu Medical”) completed its RMB 100 million Series A financing round, co-led by YuanBio Venture Capital and Med-Fine Capital.Med-Fine Capital served as the exclusive financial advisor in this transaction. FundraisingThe funds will be used to bolster Shuimu Medical’s operational capabilities, expand production capacity, advance information technology infrastructure, and enhance testing capabilities.

As the scale of China’s medical device market continues to expand and the pace of localization accelerates, the shortcomings of the domestic medical device testing and inspection market—namely, its single-mode structure and insufficient supply—have become increasingly prominent. Issues such as inadequate testing capacity, along with deficiencies in compliance design, reliability design, and usability design during product development, have significantly increased the time and economic costs associated with the registration and market launch of innovative medical devices, thereby leading to delayed clinical adoption of these products.

Beijing Shuimu Zhonghui Science and Technology Development Co., Ltd. was established in 2017 as China’s first independently founded private third-party professional medical device testing and inspection agency. To further accelerate the registration and market launch of innovative medical devices and address the “last mile” challenges in industrialization for innovators, Shuimu Medical pioneered a one-stop, full-chain service platform integrating “engineering design, testing and inspection, clinical trials, and regulatory registration.” The company operates six specialized laboratories with nationwide leading capabilities in medical device reliability, electrical safety, electromagnetic compatibility (EMC), software testing, packaging testing, and in vitro diagnostics (IVD). It has initially established business models for mechanical-electronic compliance, reliability, usability, and efficacy enhancement analysis for large-scale medical equipment such as proton and heavy ion therapy systems, surgical robots, and radiotherapy devices. By forming an engineering rectification system, it supports enterprises in product innovation and upgrading. Additionally, in the IVD sector, Shuimu Medical has built a comprehensive service platform for domestically developed, full-category diagnostic reference materials (control materials), offering products and services including third-party control materials, custom reference materials, and contracted development and manufacturing organization (CDMO) services for calibrators and control materials. It is estimated that this platform can effectively shorten the market launch cycle for medical devices by 4.5 years and reduce economic costs for enterprises by 60%.

By the end of 2020, Shuimu Medical obtained the qualification as an inspection and testing institution approved by the Certification and Accreditation Administration of the People's Republic of China (National-level CMA Accreditation) and the certificate from the China National Accreditation Service for Conformity Assessment (CNAS). It was accredited for a total of 821 inspection and testing standards, basically covering more than 90% of the testing items for active medical devices and in vitro diagnostics.

Shuimu Medical aims to grow into a world-class technology platform for the productization of medical devices, empowering innovative medical device companies, biopharmaceutical enterprises, and clinical and research institutions. By continuously developing innovative and reliable medical device technologies and products, Shuimu Medical is committed to growing alongside its clients and advancing the development and standards of the medical device industry. Following the completion of this round of financing, Shuimu Medical will further strengthen its technology platform, system construction, and capability expansion, improve the efficiency of R&D innovation and technological iteration, and explore more efficient pathways for translating medical research into industrial applications. Together with its clients, Shuimu Medical will bring more innovative medical products to clinical application, ultimately benefiting patients.

YuanBio Venture Capital, established in 2013, is an investment firm specializing in early-stage and growth-stage healthcare and medical companies. Headquartered at Suzhou BioBAY, it maintains a global reach. Currently managing approximately RMB 6 billion in assets, YuanBio has invested in over 100 high-quality projects spanning biopharmaceuticals, medical devices, diagnostics and precision medicine, and healthcare services. The firm has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 Venture Capital Funds in China’s healthcare sector and as one of the Most Active Healthcare Investment Institutions in China. YuanBio brings together a team of seasoned professional investors and world-class scientific advisors, possessing extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related fields. Committed to growing alongside outstanding startups and partners, YuanBio strives to promote the faster and better development of China’s healthcare industry.

Med-Fine Capital is a professional investment fund dedicated to the pharmaceutical, healthcare, and life sciences sectors. The fund’s team boasts extensive industry background, abundant resources, and specialized investment expertise in pharmaceuticals and healthcare. To date, Med-Fine Capital has invested in nearly fifty emerging enterprises, including TianGuangShi Biologics, Hanyu Medical, ZhenRong Pharma, ImmuneOnco, Qiuzhen Medicine, LinkMed, Ansong Technology, Micron Biotech, Pengli Biology, Libang Pharmaceutical, Yehui Pharmaceuticals, Zhongyi Anke, and CAS Gene. Adhering to its philosophy of “focusing on pharmaceuticals, healthcare, and life sciences, leveraging capital value, and rewarding trust,” Med-Fine Capital strives to become an open, platform-oriented professional pharmaceutical investment fund with outstanding international competitiveness and far-reaching reputation.

StartPointAdvisors, established in 2020, is a financial advisory firm specializing in the healthcare and medical industry. As one of the most active emerging healthcare financial advisors in the Chinese market in recent years, StartPointAdvisors has successfully completed more than 10 landmark transactions with a total value exceeding RMB 3 billion since its inception. The team at StartPointAdvisors comprises professionals from renowned industry institutions, all possessing extensive practical experience. The company currently maintains offices in Beijing and Suzhou.